Effects of Topical Diclofenac on Tumor Metabolism

NCT ID: NCT01935531

Last Updated: 2016-03-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 38 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-06-30
• Study Completion Date: 2016-03-31

Brief Summary

The rationale of this study is to investigate the effects of topical diclofenac on tumor metabolism in the treatment of actinic keratoses in immunocompetent and immunocompromised patients.

Study hypothesis is that topical diclofenac lowers lactate level in skin biopsies of actinic keratoses. Planned number of patients is 38.

This study is a monocenter study investigating the effects of 3% diclofenac in 2.5% hyaluronic acid gel on tumor metabolism in the treatment of actinic keratoses. Treatment duration is 3 months. Skin biopsies will be obtained before treatment, at the end of the treatment and four weeks after the treatment. Control biopsies at visit 1 and 3 are performed in healthy, sun damaged and untreated skin. Evaluation of efficacy will be performed at the end of the treatment and four weeks after the treatment.

Duration of treatment is 3 months (±4 weeks). Approximately 0,5g Solaraze® 3% gel is applied on a 5cm x 5cm lesion. Solaraze® 3% gel is applied twice daily on the study lesions.

Detailed Description

Neoplastic cells show an increased glucose metabolism and glycolysis which is associated with high lactate concentrations. There is also data for several tumor entities that high levels of lactate in the tumor are associated with tumor progression, metastasis and poor clinical outcome. Kreutz et al. demonstrated that diclofenac inhibits tumor cell proliferation in vitro and tumor growth in vivo via COX-independent effects on glucose metabolism. Diclofenac is taken up by tumor cells and inhibits tumor cell proliferation through inhibition of the oncogene MYC and subsequently glycolysis and block of lactate transport. MYC regulates genes involved in glycolysis and is upregulated in neoplastic cells, which is in line with the metabolic switch to glycolysis, the so called "Warburg effect", that cancer cells show. Although these results were found in vitro using human melanoma cells and in vivo in a mouse model, a similar mechanism of action is assumed to be relevant for the treatment of actinic keratoses with topical diclofenac. However tumor metabolism in diclofenac-treated actinic keratoses has never been investigated. To investigate the mechanism of action of diclofenac in the treatment of actinic keratoses, a clinical study analyzing particularly lactate levels, glycolysis and inflammatory infiltrate is needed.

Conditions

Actinic Keratoses

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Diclofenac

3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is applied twice daily in the treatment area. 3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is to be applied 1cm beyond the single AK.

Group Type: EXPERIMENTAL

3% diclofenac in 2.5% hyaluronic acid gel

Intervention Type: DRUG

Interventions

3% diclofenac in 2.5% hyaluronic acid gel

Intervention Type: DRUG

Other Intervention Names

Solaraze Gel

Eligibility Criteria

Inclusion Criteria

• Written informed consent has been signed prior to or at Screening Visit
• Caucasian male and female patients
• Age > 18 years
• Negative pregnancy test in women of childbearing age
• Clinical diagnosis of actinic keratosis (AK)
• A minimum of three AK lesions

Exclusion Criteria

• Concomitant UV-phototherapy
• Pregnancy or lactation
• Women in child-bearing age who do not use highly efficient contraceptive methods (<1% failure rate per year)
• Skin diseases that might interfere with response evaluation of study treatment
• Topical pretreatment of the AK study lesions with photodynamic therapy, Solaraze® 3% gel, Aldara®, 5-FU, or polyphenon E during the 8 weeks preceding study treatment
• Radiation therapy performed in the treatment area during the 3 months preceding study therapy
• Systemic treatment with diclofenac
• Known intolerance to diclofenac or to any other ingredient of Solaraze® 3% gel
• Conditions that might interfere with the ability to understand the study and thus give written informed consent
• Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding inclusion
• Suspected lack of compliance

• Concomitant UV-phototherapy
• Pregnancy or lactation
• Women in child-bearing age who do not use highly efficient contraceptive methods (<1% failure rate per year)
• Patients with clinically relevant suppression of the immune system (e.g. drug induced, infection)
• Skin diseases that might interfere with response evaluation of study treatment
• Topical pretreatment of the AK study lesions with photodynamic therapy, Aldara®, Solaraze® 3% gel , 5-FU, or polyphenon E during the 8 weeks preceding study treatment
• Systemic treatment with cytostatic drugs or radiation therapy performed in the treatment area during the 3 months preceding study therapy
• Systemic treatment with diclofenac
• Known intolerance to diclofenac or to any other ingredient of Solaraze® 3% gel
• Conditions that might interfere with the ability to understand the study and thus give written informed consent
• Simultaneous participation in another clinical study or participation in another clinical study in participation in another clinical study in the 30 days directly preceding inclusion
• Suspected lack of compliance

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

German Research Foundation

OTHER

Sponsor Role: collaborator

University Hospital Regensburg

OTHER

Sponsor Role: lead

Responsible Party

Professor Dr. Sigrid Karrer

Professor Dr.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

University hospital Regensburg

Regensburg, Bavaria, Germany

Countries

Germany

References

Singer K, Dettmer K, Unger P, Schonhammer G, Renner K, Peter K, Siska PJ, Berneburg M, Herr W, Oefner PJ, Karrer S, Kreutz M, Datz E. Topical Diclofenac Reprograms Metabolism and Immune Cell Infiltration in Actinic Keratosis. Front Oncol. 2019 Jul 3;9:605. doi: 10.3389/fonc.2019.00605. eCollection 2019.

Reference Type: DERIVED

PMID: 31334125 (View on PubMed)

Other Identifiers

Diclo-TuMet_01

Identifier Type: -

Identifier Source: org_study_id